Chiyoda Global Headquarters
Minato Mirai Grand Central Tower
4-6-2, Minatomirai, Nishi-ku,
Yokohama 220-8765, Japanwww.chiyodacorp.com/en

The presentation was held in Japanese.

February 10, 2021

This document is a translation/summary

IR, PR & CSR Department

for reference only.

Chiyoda Corporation

Summary of the Briefing of the Third Quarter Financial Results
for the Fiscal Year Ending March 31, 2021

The following is a summary of a presentation (telephone conference) outlining Chiyoda
Corporation’s (“Chiyoda”, TSE: 6366) financial results for the third quarter of fiscal year ending
March 31, 2021, released on February 2, 2021. Please also refer to the “Financial Results for the
3rd Quarter of Fiscal Year Ending March 31, 2021” on our website.

[Presentation Material]
1. Highlights（P1）Financial results progressed steadily with revenue and net profit achieving 87% and 92% of fullyear forecasts respectively.

Large-scale overseas orders are anticipated to reach Final Investment Decision (FID) in the 4Qof this fiscal year.

Chiyoda is promoting growth in ‘Green Energy’ (including hydrogen), expanding thepharmaceutical and life science business field and progressing digital transformation.

2．Income Statements（P2）Revenue was JPY 243 billion, 87% of the full year forecast.

Gross profit was JPY 15.5 billion, 60% of the full year forecast.

Gross profit margin was 6.4%, compared to the full-year forecast of 9.3%. Ongoing project
costs were reassessed in response to COVID-19. New order FID delays resulted in decreased
production ratio.

SG&A expenses were JPY 9.4 billion, a reduction of JPY 2.5 billion compared to the same period
last year as a result of cost reductions.

Net profit was JPY 6.5 billion, 92% of the full-year forecast.

1

Chiyoda Global Headquarters
Minato Mirai Grand Central Tower
4-6-2, Minatomirai, Nishi-ku,
Yokohama 220-8765, Japanwww.chiyodacorp.com/en

3．Balance Sheet（P3）Total assets were JPY 333.7 billion, a reduction of JPY 51.4 billion compared to the same period
last year. This is due to reductions in cash and deposits and jointly controlled assets of JV’s andoperating liabilities, coupled with the progress of ongoing projects such as the completion ofCameron LNG.

Shareholder’s equity was JPY 32.4 billion at the end of December 2020 with an improved
shareholder’s equity ratio of 9.7%. Chiyoda is aiming for a shareholder’s equity ratio of 20% withsteadily increasing profits in line with the Medium-term Management Plan.

4．Profit Analysis（P4）This slide shows the breakdown of gross profits in the energy business and global business fields.
It also shows the breakdown of gross profits of projects awarded before and after theRevitalization Plan.

The gross profit of JPY 15.5 billion in the third quarter includes negative JPY 1.5 billion from theglobal environment business field. Ongoing domestic project costs were reassessed in the thirdquarter in response to COVID-19. Ongoing project profits are anticipated to recover in the fourth
quarter along with gains in the global environment business field at the end of the fiscal year.

Project gross profits before and after the Revitalization Plan were JPY 5.2 billion and JPY 10.3
billion respectively, showing steady profit gains after the release of the plan in May 2019.

SG&A expenses reduced by JPY 2.5 billion compared to the same period last year as a result ofcost reductions.



Non-operating income is JPY 0.1 billion mainly due to foreign exchange profit. Extraordinary
income and income taxes are JPY 0.2 billion due to sales of shares of subsidiaries and associates
and a corporate tax refund in the USA. Profit attributable to owners of the parent amounted to
JPY 6.5 billion.

As a result of the above, shareholder‘s equity was JPY 32.4 billion with an improved shareholder’sequity ratio of 9.7%.

5．New Orders / Backlog（P5）New orders in the third quarter stood at JPY 102.8 billion. New orders are expected as FID’s forlarge-scale overseas projects are planned for the fourth quarter of this fiscal year.

In the global environment business field, orders were secured in pharmaceuticals and lifesciences.

The order backlog was JPY 626.8 billion.
2

Chiyoda Global Headquarters
Minato Mirai Grand Central Tower
4-6-2, Minatomirai, Nishi-ku,
Yokohama 220-8765, Japanwww.chiyodacorp.com/en

6．The full-year consolidated forecast remains unchanged.

Attachment
Breakdown of Revenue, New Orders and Backlog（P6～P8）(Omitted)

AppendixI.)

Growth Strategy（P10～P15）

1．Green Energy （P10）This slide shows Chiyoda’s growth strategy in the Green Energy field, with priority strategies
circled in green.

Commencing from upstream low carbonization of fossil fuels and renewable energy, Chiyoda’sbusiness flows downstream to rechargeable batteries and energy management.

Hydrogen utilization technology is Chiyoda’s core growth strategy in the Green Energy field.

2．SPERA Hydrogen （P11）As posted in NIKKEI on February 2, 2021, the world’s first global hydrogen supply chain
demonstration system, including SPERA Hydrogen technology, was successfully completed inDecember 2020 and Chiyoda is progressing towards commercialization.

Chiyoda is proud to propose SPERA Hydrogen as a practical solution towards a hydrogen society.

3Chiyoda Global Headquarters
Minato Mirai Grand Central Tower
4-6-2, Minatomirai, Nishi-ku,
Yokohama 220-8765, Japanwww.chiyodacorp.com/en

3. Carbon Capture （P12）Chiyoda completed a CO2 Separation and Recovery plant to capture CO2 emitted by thermal
power plants in October 2020.

Chiyoda’s CT-121 process is used to fuel gas desulfurization facilities.

A plant to capture over 50% of CO2 emitted by thermal power plant is the first of its kind in Japan.

4. Energy Management （P13）Chiyoda is proceeding with energy management through the stable supply of renewable energy
using a battery energy storage system. The world’s largest battery energy storage system iscurrently under construction in Hokkaido.

5．Pharmaceutical / Life Science （P14）Chiyoda was awarded an EPC contract from Shionogi & Co., Ltd. last year for the constructionof plant to manufacture a COVID-19 vaccine drug constituent from genetically modified protein.

Chiyoda aims to establish continuous manufacturing technology, applying its expertise in thehydrogenation reaction process in petroleum refining and technology for API’s and Intermediates.

Chiyoda is expanding its pharmaceutical / life science business field in response to increased
health awareness.

6．Digital Transformation （P15）EFEXISTM is Chiyoda’s digital product brand, visualizing and automating plant operation andmaintenance without the need for large-scale modifications, and improving customer asset
values through operation optimization and maintenance efficiency.

Chiyoda is promoting PlantStreamTM for plant engineering, an innovative engineering system that
reduces approximately 80% of basic process engineering and improves the speed of 3Dengineering by up to about 5 times, by combining plant engineering expertise with CAD andoptimization technology knowledge.

4Chiyoda Global Headquarters
Minato Mirai Grand Central Tower
4-6-2, Minatomirai, Nishi-ku,
Yokohama 220-8765, Japanwww.chiyodacorp.com/enII.) Major Ongoing Projects（P16）In cooperation with our clients, ongoing projects continue with measures against the spread ofCOVID-19.

-End-Please address inquiries to: IR, PR & CSR Department: Tel. +81-45-225-7734

Note: Some additions and corrections have been made to simplify the content for readers. Any
projections included in these materials are based solely on information available at the time thispresentation was prepared. It is possible that actual results may vary significantly from the projections
due to a number of risk factors such as economic conditions. The results projected here should not
be construed in any way as being guaranteed by the Company. Investors are recommended not todepend solely on these projections for making investment decisions.

5